Diagnostik und Therapie des Multiplen Myelom

Zusammenfassung

Das Multiple Myelom ist eine maligne Erkrankung antikörperproduzierender Plasmazellen. Die Klinik ist charakterisiert durch Verdrängung der gesunden Hämatopoese, osteolytische Knochenkrankheit und Paraproteinämie/-urie. Letztere ist Ursache für Myelomnephropathie, Hyperviskositätssyndrome und Mangel an funktionsfähigen Antikörpern. In den letzten 30 bis 40 Jahren konnten enorme Forschritte bezüglich Therapieoptionen, Gesamtprognose und molekularer Pathophysiologie der Erkrankung erreicht werden. Daher wurden die Definitionen monoklonaler Gammopathien, die Stadieneinteilung, die Prognosefaktoren und die Kriterien für das Ansprechen neu definiert. Die Hochdosistherapie mit autologer Stammzelltransplantation ist heute Standardtherapie für die jüngeren Patienten. Ferner wurden neuartige Zytostatika zugelassen (z.B. Bortezomib, Lenalidomid), andere sind in klinischer Prüfung oder präklinischer Entwicklung. Dadurch sind auch bei älteren Patienten mit Komorbidität sichere und effektive Therapien möglich. Diese Übersichtsarbeit beschreibt die aktuellen Standards bezüglich Diagnose, Stadieneinteilung und Therapie des Multiplen Myelom.

Summary

Multiple Myeloma (MM) is a malignant disease of plasma cells which is characterized by hematopoietic insufficiency, bone destruction, and overproduction of monoclonal antibodies that cause renal failure, hyperviscosity, and immune deficiency. Over the past three to four decades tremendous progress was achieved concerning therapeutic options and overall prognosis but as well concerning the knowledge of the molecular basis of the disease. Therefore the definition of monoclonal gammopathies, the staging system of MM, the prognostic markers, and the response criteria needed to be revised. High-dose chemotherapy with autologous stem cell support has evolved to standard of care in younger patients. Additionally, novel therapeutic compounds have been approved (e.g. bortezomib, lenalidomide), others are in clinical testing or in preclinical development. Therefore, save and effective treatments can be offered also to elderly patients with comorbidity. The current standards for diagnosis, staging, and treatment of MM are summarized in this review.

Multiples Myelom - monoklonale Gammopathien - Prognosefaktoren - Diagnose - Therapie

Multiple Myeloma - monoclonal gammopathies - prognostic markers - diagnosis - treatment

Literatur

• 01 Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J. et al . Combination chemotherapy for multiple myeloma.  Cancer. 1972;  30 382-9
• 02 Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C. et al . Single versus double autologous stem-cell transplantation for multiple myeloma.  N Engl J Med. 2003;  349 2495-502
• 03 Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G. et al . A prospective, randomized trial of autologous bone marrow transplantation andchemotherapy in multiple myeloma.  N Engl J Med. 1996;  335 91-7
• 04 Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F. et al . Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome.  Blood. 2007;  109 3489-95
• 05 Barlogie B, Kyle R A, Anderson K C, Greipp P R, Lazarus H M. et al . Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.  J Clin Oncol 2006;  24 929-36
• 06 Bladé J, Rosiñol L, Sureda A, Ribera J M, Díaz-Mediavilla J. et al . High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.  Blood. 2005;  106 3755-9
• 07 Child J A, Morgan G J, Davies F E, Owen R G, Bell S E. et al . High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.  N Engl J Med. 2003;  348 1875-83
• 08 Durie B G, Salmon S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to reatment and survival.  Cancer. 1975;  36 842-54
• 09 Facon T, Mary J Y, Hulin C, Benboubker L, Attal M. et al . Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.  Lancet. 2007;  370 1209-18
• 10 Ferlay J, Bray F, Pisani P, Parkin D M. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. IARC CancerBase No. 5 Lyon; IARCPress 2001
• 11 Fermand J P, Katsahian S, Divine M, Leblond V, Dreyfus F. et al . High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.  J Clin Oncol. 2005;  23 9227-33
• 12 Fonseca R, Harrington D, Oken M M, Dewald G W, Bailey R J. et al . Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.  Cancer Res. 2002;  62 715-20
• 13 Gregory W M, Richards M A, Malpas J S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.  J Clin Oncol. 1992;  10 334-42
• 14 Greipp P R, San Miguel J, Durie P G, Crowley J J, Barlogie B. et al . International staging system for multiple myeloma.  J Clin Oncol. 2005;  23 3412-20
• 15 Hideshima T, Bergsagel P L, Kuehl W M, Anderson K C. Advances in biology of multiple myeloma: clinical applications.  Blood. 2004;  104 607-18.2
• 16 International Myeloma Working Group . Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.  Br J Haematol. 2003;  121 749-57
• 17 Jagannath S, Richardson P G, Sonneveld P, Schuster M W, Irwin D. et al . Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.  Leukemia. 2007;  21 151-7
• 18 Koreth J, Cutler C S, Djulbegovic B, Behl R, Schlossman R L. et al . High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.  Biol Blood Marrow Transplant. 2007;  13 183-96
• 19 Lévy V, Katsahian S, Fermand J P, Mary J Y, Chevret S. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy.  Medicine (Baltimore). 2005;  84 250-60
• 20 Mateos M V, Hernández J M, Hernández M T, Gutiérrez N C, Palomera L. et al . Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.  Blood. 2006;  108 2165-72
• 21 Myeloma Trialistsӱ Collaborative Group . Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.  J Clin Oncol. 1998;  16 3832-42
• 22 Osgood E E. The survival time of patients with plasmocytic myeloma.  Cancer Chemother Rep. 1960;  9 1-10
• 23 Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V. et al . Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.  Lancet. 2006;  367 825-31
• 24 Palumbo A, Bringhen S, Petrucci M T, Musto P, Rossini F. et al . Intermediate-Dose Melphalan Improves Survival of Myeloma Patients Aged 50-70: Results of A Randomised Controlled Trial.  Blood. 2004;  104 3052-7
• 25 Palumbo A, Falco P, Falcone A, Di Raimondo F. et al . Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian Multiple Myeloma Network.  J Clin Oncol. 2007;  25 4459-65
• 26 Russel N H, Miflin G, Stainer C, McQuaker J G, Bienz N. et al . Allogeneic bone marrow transplant for multiple myeloma.  Blood. 1997;  89 2610-11
• 27 Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N. et al . Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13 q-deletion.  Leukemia. 2007;  21 164-8
• 28 Straka C, Liebisch P, Hennemann B, Metzner B, Salwender S. et al . The Effects of Induction Chemotherapy and High-Dose Melphalan with Tandem Autologous Transplantation in Multiple Myeloma: The Prospective Randomized DSMM 2 Study.  Blood. 2007;  110
• 29 Trudel S, Stewart A K, Rom E, Wei E, Li Z H. et al . The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t (4; 14) multiple myeloma cells.  Blood. 2006;  107 4039-46
• 30 Rhee F van, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E. et al . High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.  Blood. 2007;  110 827-32

Korrespondenzadresse